UNSPSC 51384533: Naproxen sodium

This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H13O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9TN87S3A3C, chemically known as 2-naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (s)- but more generally known as naproxen sodium, which bears US NIH Compound Identifier 1302. European Medicines Agency schedules Naproxen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03392MIG.

Most nations, for tariff and trade purposes, schedule naproxen sodium under HS 29189900 and SITC 51396. As of Q4 2014, NAPROXEN SODIUM remains US FDA's Preferred Term for this commodity. Naproxen sodium bears US NLM identifiers UMLS ID C0546873 and NCI Concept Code C48006. SMILES: C[C@@H](C1CCC2CC(CCC2C1)OC)C(=O)[O-].[NA+].

UNSPSC 51384533 Naproxen sodium is a Commodity code that in practice covers a broader range of pharmaceuticals and over-the-counter products procured by state and local health agencies, not naproxen exclusively. Recent state and local solicitations under this code actually seek generic multi-source pharmaceuticals, naloxone, and OTC products for distribution through public health systems, community health programs, and pharmacy benefit programs. Issuing bodies include state health and human services departments, county health agencies, and cooperative purchasing alliances representing multiple state and local jurisdictions. The Texas Health and Human Services Commission, Minnesota Department of Administration, and Seminole County, Florida have all posted solicitations in this space within the past four months, signaling sustained procurement activity among larger state systems and regional cooperative vehicles.

The code sees active procurement in Texas, Minnesota, Florida, and Oregon (through MMCAP participation). Representative recent opportunities include the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026), which established multiple contracts effective July 1, 2026 with distribution through authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson; Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (due July 26, 2023); and the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (due April 3, 2026), which signals emerging state interest in alternative pharmacy benefit procurement models. MMCAP's RFP weighted price competitiveness at 75 percent and required vendors to maintain $5,000,000 commercial general liability coverage and comply with cGMP and DSCSA certifications. Vendors should expect administrative fees (MMCAP charged 3 percent) and multi-year contract terms with performance penalty structures.